| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 08/05/2024 | 22:49 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:SANA | Sana Biotechnology Inc |
| 08/05/2024 | 22:21 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:SANA | Sana Biotechnology Inc |
| 08/05/2024 | 22:13 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:SANA | Sana Biotechnology Inc |
| 08/05/2024 | 22:05 | GlobeNewswire Inc. | Sana Biotechnology Reports First Quarter 2024 Financial Results and Business Updates | NASDAQ:SANA | Sana Biotechnology Inc |
| 06/05/2024 | 22:05 | GlobeNewswire Inc. | Sana Biotechnology to Present at May and June 2024 Investor Conferences | NASDAQ:SANA | Sana Biotechnology Inc |
| 08/03/2024 | 22:17 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:SANA | Sana Biotechnology Inc |
| 29/02/2024 | 22:05 | GlobeNewswire Inc. | Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | NASDAQ:SANA | Sana Biotechnology Inc |
| 28/02/2024 | 22:05 | GlobeNewswire Inc. | Sana Biotechnology to Present at the Cowen 44th Annual Health Care Conference | NASDAQ:SANA | Sana Biotechnology Inc |
| 14/02/2024 | 22:00 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:SANA | Sana Biotechnology Inc |
| 13/02/2024 | 22:05 | GlobeNewswire Inc. | Sana Biotechnology Announces Publication of Preclinical Diabetes Data in Cell Stem Cell Demonstrating Insulin Independence Following Transplantation of Hypoimmune Allogeneic Primary Islet Cells Without Immunosuppression in a Diabetic NHP | NASDAQ:SANA | Sana Biotechnology Inc |
| 12/02/2024 | 22:05 | GlobeNewswire Inc. | Sana Biotechnology Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares | NASDAQ:SANA | Sana Biotechnology Inc |
| 08/02/2024 | 22:49 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] | NASDAQ:SANA | Sana Biotechnology Inc |
| 08/02/2024 | 07:22 | GlobeNewswire Inc. | Sana Biotechnology Announces Pricing of Upsized Public Offering | NASDAQ:SANA | Sana Biotechnology Inc |
| 08/02/2024 | 03:59 | Edgar (US Regulatory) | Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses | NASDAQ:SANA | Sana Biotechnology Inc |
| 07/02/2024 | 22:01 | GlobeNewswire Inc. | Sana Biotechnology Announces Proposed Public Offering of Common Stock | NASDAQ:SANA | Sana Biotechnology Inc |
| 05/01/2024 | 15:00 | GlobeNewswire Inc. | Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC262, a Hypoimmune-modified, CD22-directed Allogeneic CAR T Therapy, for Patients with Relapsed or Refractory B-cell Malignancies | NASDAQ:SANA | Sana Biotechnology Inc |
| 03/01/2024 | 22:05 | GlobeNewswire Inc. | Sana Biotechnology to Present at the 42nd Annual J.P. Morgan Healthcare Conference | NASDAQ:SANA | Sana Biotechnology Inc |
| 15/12/2023 | 22:34 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:SANA | Sana Biotechnology Inc |
| 11/12/2023 | 15:00 | GlobeNewswire Inc. | Sana Biotechnology Highlights Preclinical Data Supporting Tumor Control and Immune Evasion Capabilities of Hypoimmune-Modified Allogeneic CAR T Cells in Presentations at the American Society of Hematology Annual Meeting | NASDAQ:SANA | Sana Biotechnology Inc |
| 01/12/2023 | 22:05 | GlobeNewswire Inc. | Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System | NASDAQ:SANA | Sana Biotechnology Inc |
| 28/11/2023 | 01:01 | PR Newswire (US) | Flagship Pioneering Marks Official Opening of UK Hub with Event Convening Life Science Leaders | NASDAQ:SANA | Sana Biotechnology Inc |
| 21/11/2023 | 15:00 | GlobeNewswire Inc. | Sana Biotechnology to Present at November and December 2023 Investor Conferences | NASDAQ:SANA | Sana Biotechnology Inc |
| 21/11/2023 | 12:00 | PR Newswire (US) | Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics | NASDAQ:SANA | Sana Biotechnology Inc |
| 17/11/2023 | 15:00 | GlobeNewswire Inc. | Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes | NASDAQ:SANA | Sana Biotechnology Inc |
| 09/11/2023 | 22:05 | GlobeNewswire Inc. | Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis | NASDAQ:SANA | Sana Biotechnology Inc |
| 08/11/2023 | 22:05 | GlobeNewswire Inc. | Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates | NASDAQ:SANA | Sana Biotechnology Inc |
| 02/11/2023 | 14:05 | GlobeNewswire Inc. | Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting | NASDAQ:SANA | Sana Biotechnology Inc |
| 01/11/2023 | 15:30 | PR Newswire (US) | Flagship Pioneering Launches Pioneering Intelligence | NASDAQ:SANA | Sana Biotechnology Inc |
| 10/10/2023 | 22:15 | GlobeNewswire Inc. | Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M | NASDAQ:SANA | Sana Biotechnology Inc |
| 11/09/2023 | 12:30 | PR Newswire (US) | Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer | NASDAQ:SANA | Sana Biotechnology Inc |